Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 176, Issue 3, 2007, Pages 261-269

  Doucet, Mariève ^a   Russell, Aaron P ^b,c   Léger, Bertrand ^b   Debigaré, Richard ^a   Joanisse, Denis R ^d   Caron, Marc André ^a   LeBlanc, Pierre ^a   Maltais, François ^a  

^a LAVAL UNIVERSITY   (Canada)

^b SUVA   (Switzerland)

^c DEAKIN UNIVERSITY   (Australia)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

AKT; Chronic obstructive pulmonary disease; E3 ligases; Forkhead box class O 1; Muscle wasting

Indexed keywords

BINDING PROTEIN; FORKHEAD BOX PROTEIN O 1; FORKHEAD BOX PROTEIN O 3; FORKHEAD TRANSCRIPTION FACTOR; GLYCOGEN SYNTHASE KINASE 3BETA; INITIATION FACTOR 4E; MESSENGER RNA; PROTEIN ATROGIN 1; PROTEIN KINASE B; PROTEIN MUSCLE RING FINGER 1; S6 KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; MALE; MUSCLE ATROPHY; MUSCLE HYPERTROPHY; MUSCLE MASS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUADRICEPS FEMORIS MUSCLE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 34547601994     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200605-704OC     Document Type: Article

References (48)

1. Agusti AGN, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-360.
2. Wouters EFM. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:26-33.
3. Marquis K, Debigare R, Lacasse Y, LeBlanc P, Jobin J, Carrier G, Maltais F. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:809-813.
4. Debigaré R, Côté CH, Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease, clinical relevance and mechanisms. Am J Respir Crit Care Med 2001;164:1712-1717.
5. Debigaré R, Marquis K, Côté CH, Tremblay RR, Michaud A, LeBlanc P, Maltais F. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003;124:83-89.
6. Nader GA. Molecular determinants of skeletal muscle mass: getting the "AKT" together. Int J Biochem Cell Biol 2005;37:1985-1996.
7. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004;14:395-403.
8. Bodine SC, Latres E, Baumhueter S, Lai VKM, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-1708.
9. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. FoxO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004;117:399-412.
10. Van Der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 2004;380:297-309.
11. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 2005;37:1974-1984.
12. Reynolds TH IV, Bodine SC, Lawrence JC Jr. Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J Biol Chem 2002;277:17657-17662.
13. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002;16:1472-1487.
14. Hardt SE, Sadoshima J. Glycogen synthase kinase-3β: a novel regulator of cardiac hypertrophy and development. Circ Res 2002;90:1055-1063.
15. Doucet M, Russell AP, Debigaré R, Joanisse DR, LeBlanc P, Maltais F. Activation of the ubiquitin-proteasome pathway in patients with stable chronic obstructive pulmonary disease (COPD) and muscle wasting [abstract]. Proc Am Thorac Soc 2006;3:A26.
16. Couillard A, Maltais F, Saey D, Debigaré R, Michaud A, Koechlin C, LeBlanc P, Préfaut C. Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:1664-1669.
17. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152(Suppl):S77-S120.
18. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40.
19. Heymsfield SB, Williams PJ. Nutritional assessment by clinical and biochemical methods. In: Shils ME, Olson JA, editors. Modern nutrition in health and disease. Philadelphia: Lea & Febiger; 1994. pp. 812-841.
20. Bergström J. Muscle electrolytes in man: determination by neutron activation analysis on needle biopsy specimens: a study on normal subjects, kidney patients and patients with chronic diarrhoea. Scand J Clin Lab Invest 1962;14:1-110.
21. Whittom F, Jobin J, Simard PM, LeBlanc P, Simard C, Bernard S, Belleau R, Maltais F. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc 1998;30:1467-1474.
22. Cartoni R, Leger B, Hock MB, Praz M, Crettenand A, Pich S, Ziltener JL, Luthi F, Deriaz O, Zorzano A, et al. Mitofusins 1/2 and ERRα expression are increased in human skeletal muscle after physical exercise. J Physiol 2005;567:349-358.
23. Russell AP, Hesselink MKC, Lo SK, Schrauwen P. Regulation of metabolic transcriptional co-activators and transcription factors with acute exercise. FASEB J 2005;19:986-988.
24. Leger B, Vergani L, Soraru G, Hespel P, Derave W, Gobelet C, D'Ascenzio C, Angelini C, Russell AP. Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin-1. FASEB J 2006;20:583-585.
25. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001;98:14440-14445.
26. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004;18:39-51.
27. Rutten EPA, Franssen FME, Engelen MPKJ, Wouters EFM, Deutz NEP, Schols AMWJ. Greater whole-body myofibrillar protein breakdown in cachectic patients with chronic obstructive pulmonary disease. Am J Clin Nutr 2006;83:829-834.
28. Szewczyk NJ, Jacobson LA. Signal-transduction networks and the regulation of muscle protein degradation. Int J Biochem Cell Biol 2005;37:1997-2011.
29. Agusti A, Morla M, Sauleda J, Saus C, Busquets X. NF-kB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 2004;59:483-487.
30. Cai D, Frantz JD, Tawa NE, Melendez PA, Oh BC, Lidov HGW, Hasselgren PO, Frontera WR, Lee J, Glass DJ, et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell 2004;119:285-298.
31. Burgering BM, Medema RH. Decisions on life and death: FOXO forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol 2003;73:689-701.
32. Kamei Y, Miura S, Suzuki M, Kai Y, Mizukami J, Taniguchi T, Mochida K, Hata T, Matsuda J, Aburatani H, et al. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 2004;279:41114-41123.
33. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, et al. IkB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004;117:225-237.
34. Li M, Li C, Parkhouse WS. Age-related differences in the des IGFI-mediated activation of Akt-1 and p70 S6K in mouse skeletal muscle. Mech Ageing Dev 2003;124:771-778.
35. Childs TE, Spangenburg EE, Vyas DR, Booth FW. Temporal alterations in protein signaling cascades during recovery from muscle atrophy. Am J Physiol Cell Physiol 2003;285:C391-C398.
36. Morris RT, Spangenburg EE, Booth FW. Responsiveness of cell signaling pathways during the failed 15-day regrowth of aged skeletal muscle. J Appl Physiol 2004;96:398-404.
37. Bodine SC. mTOR signaling and the molecular adaptation to resistance exercise. Med Sci Sports Exerc 2006;38:1950-1957.
38. Kimball SR, Farrell PA, Jefferson LS. Exercise effects on muscle insulin signaling and action: invited review: role of insulin in translational control of protein synthesis in skeletal muscle by amino acids or exercise. J Appl Physiol 2002;93:1168-1180.
39. Gosker HR, Kubat B, Schaart G, van der Vusse GJ, Wouters EFM, Schols AMWJ. Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease. Eur Respir J 2003;22:280-285.
40. Montes de Oca M, Torres SH, De Sanctis J, Mata A, Hernandez N, Talamo C. Skeletal muscle inflammation and nitric oxide in patients with COPD. Eur Respir J 2005;26:390-397.
41. Schols AMWJ, Buurman WA, Staal-van den Brekel AJ, Dentener MA, Wouters EFM. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996;51:819-824.
42. Eid AA, Ionescu AA, Nixon LS, Lewis-Jenkins VANE, Matthews SB, Griffiths TL, Shale DJ. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1414-1418.
43. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210-215.
44. Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, Bouillon R, Decramer M. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003;58:752-756.
45. Schols AMWJ. Pulmonary cachexia. J Cardiol 2002;85:101-110.
46. Anker SD, Coats AJS. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest 1999;115:836-847.
47. Schols AMWJ, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005;82:53-59.
48. Leger B, Cartoni R, Praz M, Lamon S, Deriaz O, Crettenand A, Gobelet C, Rohmer P, Konzelmann M, Luthi F, et al. Akt signalling through GSK-3β, mTOR and FoxO1 is involved in human skeletal muscle hypertrophy and atrophy. J Physiol 2006;576:923-933.